Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis

Incannex Healthcare Limited has received approval from the Bellberry Human Research Ethics Committee (HREC) for its Phase 2 clinical trial. The trial aims to evaluate the effectiveness of IHL-675A, a unique anti-inflammatory combination drug product, in patients suffering from rheumatoid arthritis (RA). This pivotal trial comes after a successful Phase 1 study where IHL-675A demonstrated excelle..